Intercept Pharmaceuticals (ICPT) PT Lowered to $25 at Needham & Company, Analyst Does Not Anticipate Phase 3 REVERSE Trial to Have a Positive Outcome
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $25.00 (from $30.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
